Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index. The symptoms associated with carcinoid syndrome and vasoactive intestinal peptide tumors are treated with octreotide acetate....
Main Authors: | Paola Di Giacinto, Francesca Rota, Laura Rizza, Davide Campana, Andrea Isidori, Andrea Lania, Andrea Lenzi, Paolo Zuppi, Roberto Baldelli |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2018/8126087 |
Similar Items
-
CLINICAL VALUE OF CHROMOGRANIN A IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS
by: N. V. Lyubimova, et al.
Published: (2016-02-01) -
Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
by: Tatsuo Tomita
Published: (2020-02-01) -
Chromogranin A and serotonin for evaluation of treatment efficacy of neuroendocrine tumors
by: N. V. Lyubimova, et al.
Published: (2020-01-01) -
Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
by: Jonas Baekdal, et al.
Published: (2020-10-01) -
Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
by: Tiantian Tian, et al.
Published: (2016-01-01)